Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma-Reference-Cited by-同舟云学术

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma

Published:2018-10-01 Issue:10 Volume:4 Page:1382
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hauschild Axel¹,Larkin James²,Ribas Antoni³,Dréno Brigitte⁴,Flaherty Keith T.⁵,Ascierto Paolo A.⁶,Lewis Karl D.⁷,McKenna Edward⁸,Zhu Qian⁸,Mun Yong⁸,McArthur Grant A.⁹¹⁰

Affiliation:

1. University Hospital Schleswig-Holstein, Kiel, Germany

2. The Royal Marsden NHS Foundation Trust, London, England

3. The Jonsson Comprehensive Cancer Center at University of California, Los Angeles

4. Nantes University, Nantes, France

5. Massachusetts General Hospital, Boston

6. Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

7. University of Colorado Comprehensive Cancer Center, Aurora

8. Genentech Inc, South San Francisco, California

9. Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

10. University of Melbourne, Parkville, Victoria, Australia

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference21 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.;Chapman;N Engl J Med,2011

2. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.;McArthur;Lancet Oncol,2014

3. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.;Ribas;Lancet Oncol,2014

4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.;Larkin;N Engl J Med,2014

5. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.;Ascierto;Lancet Oncol,2016

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis;International Journal of Dermatology;2024-08-04

2. Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis;Cancer Research Communications;2024-08-01

3. Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses;Cancers;2024-07-17

4. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg;International Journal of Cancer;2024-07-08

5. Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance;Cell Reports Medicine;2024-07